Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gyorgy Losonczy, MD"'
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign
Externí odkaz:
https://doaj.org/article/1c079ba625de443f80bdb5548364cf07